Carsten Schwencke1, Klaudija Bijuklic2, Taoufik Ouarrak3, Edith Lubos4, Wolfgang Schillinger5,6, Björn Plicht7, Holger Eggebrecht8, Stephan Baldus9, Gerhard Schymik10, Peter Boekstegers11, Rainer Hoffmann12, Jochen Senges3, Joachim Schofer2. 1. Hamburg University Cardiovascular Center, Wördemanns Weg 25-27, 22527, Hamburg, Germany. schwencke@herz-hh.de. 2. Hamburg University Cardiovascular Center, Wördemanns Weg 25-27, 22527, Hamburg, Germany. 3. Institute for Myocardial Infarction Research Foundation, Ludwigshafen, Germany. 4. Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany. 5. HELIOS Albert-Schweizer-Klinik Northeim, Northeim, Germany. 6. Heart Center, Georg-August-University Göttingen, Göttingen, Germany. 7. Klinikum Westfalen, Dortmund, Germany. 8. Cardiovascular Center Bethanien, Frankfurt, Germany. 9. Department of Cardiology, Heart Center, University Hospital Cologne, Cologne, Germany. 10. Department of Cardiology and Angiology, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany. 11. Department of Cardiology and Angiology, HELIOS Heart Center Siegburg, Siegburg, Germany. 12. Department of Cardiology and Angiology, Bonifatius Hospital Lingen, Lingen, Germany.
Abstract
AIMS: The use of the MitraClip system has gained widespread acceptance for the treatment of patients with mitral regurgitation (MR) who are not suitable for the conventional surgery. This study sought to investigate the early and 1-year outcome after MitraClip therapy of patients with MR and cardiac comorbidities. METHODS AND RESULTS: Outcomes through 12-month follow-up of patients (n = 528) who underwent MitraClip implantation were obtained from the German transcatheter mitral valve interventions (TRAMI) registry. The majority of these patients (n = 409, 77.5 %) also suffered from coronary artery disease (CAD). Patients with a dilated cardiomyopathy (DCM, n = 65, 12.3 %) or concomitant valvular aortic disease (AV, n = 54, 10.2 %) were less frequent. Although the prevalent pathogenesis was functional MR, patients with DCM had significantly more frequent a functional MR (96.9 %) compared to patients with CAD (74.9 %) or AV (62.5 %, p < 0.001). Technical success was achieved in 97.5 % of patients. Procedural echocardiograms demonstrated in the vast majority of patients a reduction from severe MR III to mild MR I with no difference between the groups (p = 0.83). The peri-procedural complication rate was very low. At 30-day and 12-month follow-up, the majority of patients were in NYHA functional class II or lower. The rate of death, stroke, and myocardial infarction (MACCE) was comparable in the three patient groups during 12-month follow-up (DCM 26.9 %, CAD 30.3 % and AV 27.5 %, p = 0.85). CONCLUSIONS: The MitraClip implantation is feasible and safe even in high-risk patients with MR and cardiac comorbidities.
AIMS: The use of the MitraClip system has gained widespread acceptance for the treatment of patients with mitral regurgitation (MR) who are not suitable for the conventional surgery. This study sought to investigate the early and 1-year outcome after MitraClip therapy of patients with MR and cardiac comorbidities. METHODS AND RESULTS: Outcomes through 12-month follow-up of patients (n = 528) who underwent MitraClip implantation were obtained from the German transcatheter mitral valve interventions (TRAMI) registry. The majority of these patients (n = 409, 77.5 %) also suffered from coronary artery disease (CAD). Patients with a dilated cardiomyopathy (DCM, n = 65, 12.3 %) or concomitant valvular aortic disease (AV, n = 54, 10.2 %) were less frequent. Although the prevalent pathogenesis was functional MR, patients with DCM had significantly more frequent a functional MR (96.9 %) compared to patients with CAD (74.9 %) or AV (62.5 %, p < 0.001). Technical success was achieved in 97.5 % of patients. Procedural echocardiograms demonstrated in the vast majority of patients a reduction from severe MR III to mild MR I with no difference between the groups (p = 0.83). The peri-procedural complication rate was very low. At 30-day and 12-month follow-up, the majority of patients were in NYHA functional class II or lower. The rate of death, stroke, and myocardial infarction (MACCE) was comparable in the three patient groups during 12-month follow-up (DCM 26.9 %, CAD 30.3 % and AV 27.5 %, p = 0.85). CONCLUSIONS: The MitraClip implantation is feasible and safe even in high-risk patients with MR and cardiac comorbidities.
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Gregg W Stone; Alec S Vahanian; David H Adams; William T Abraham; Jeffrey S Borer; Jeroen J Bax; Joachim Schofer; Donald E Cutlip; Mitchell W Krucoff; Eugene H Blackstone; Philippe Généreux; Michael J Mack; Robert J Siegel; Paul A Grayburn; Maurice Enriquez-Sarano; Patrizio Lancellotti; Gerasimos Filippatos; Arie Pieter Kappetein Journal: J Am Coll Cardiol Date: 2015-07-21 Impact factor: 24.094
Authors: Volker Rudolph; Michael Huntgeburth; Ralph Stephan von Bardeleben; Peter Boekstegers; Edith Lubos; Wolfgang Schillinger; Taoufik Ouarrak; Holger Eggebrecht; Christian Butter; Björn Plicht; Andreas May; Olaf Franzen; Joachim Schofer; Jochen Senges; Stephan Baldus Journal: Eur J Heart Fail Date: 2014-10-15 Impact factor: 15.534
Authors: Olaf Franzen; Stephan Baldus; Volker Rudolph; Sven Meyer; Malgorzata Knap; Dietmar Koschyk; Hendrik Treede; Achim Barmeyer; Joachim Schofer; Angelika Costard-Jäckle; Michael Schlüter; Hermann Reichenspurner; Thomas Meinertz Journal: Eur Heart J Date: 2010-03-10 Impact factor: 29.983
Authors: Gregg W Stone; David H Adams; William T Abraham; Arie Pieter Kappetein; Philippe Généreux; Pascal Vranckx; Roxana Mehran; Karl-Heinz Kuck; Martin B Leon; Nicolo Piazza; Stuart J Head; Gerasimos Filippatos; Alec S Vahanian Journal: J Am Coll Cardiol Date: 2015-07-21 Impact factor: 24.094
Authors: Benjamin H Trichon; G Michael Felker; Linda K Shaw; Christopher H Cabell; Christopher M O'Connor Journal: Am J Cardiol Date: 2003-03-01 Impact factor: 2.778
Authors: Wolfgang Schillinger; Mark Hünlich; Stephan Baldus; Taoufik Ouarrak; Peter Boekstegers; Ulrich Hink; Christian Butter; Raffi Bekeredjian; Björn Plicht; Horst Sievert; Joachim Schofer; Jochen Senges; Thomas Meinertz; Gerd Hasenfuß Journal: EuroIntervention Date: 2013-05-20 Impact factor: 6.534
Authors: Steffen D Kriechbaum; Niklas F Boeder; Luise Gaede; Martin Arnold; Ursula Vigelius-Rauch; Peter Roth; Michael Sander; Andreas Böning; Matthias Bayer; Albrecht Elsässer; Helge Möllmann; Christian W Hamm; Holger M Nef Journal: Clin Res Cardiol Date: 2019-08-26 Impact factor: 5.460
Authors: Victor Mauri; Maria I Körber; Elmar Kuhn; Tobias Schmidt; Christian Frerker; Thorsten Wahlers; Tanja K Rudolph; Stephan Baldus; Matti Adam; Henrik Ten Freyhaus Journal: Clin Res Cardiol Date: 2020-02-18 Impact factor: 5.460
Authors: Lutz Frankenstein; Klaus Kaier; Hugo A Katus; Christoph Bode; Tobias Wengenmayer; Constantin von Zur Mühlen; Raffi Bekeredjian; Tobias Täger; Manfred Zehender; Hanna Fröhlich; Peter Stachon Journal: Clin Res Cardiol Date: 2020-05-27 Impact factor: 5.460